The latest update is out from Aptose Biosciences ( (TSE:APS) ).

The latest update is out from Aptose Biosciences ( (TSE:APS) ).

Among a heavily pretreated, older adult population of patients with relapsed/refractory (R/R) nucleophosmin 1-mutated (NPM1m) acute myeloid leukemia (AML), revumenib was associated with a clinically ...

Cytogenetic risk doesn't seem to explain the disparity in mortality of Black vs White patients, a study across 10 clinical ...

SELLAS Life Sciences Group, Inc. has announced significant milestones in its clinical development of cancer therapies. An Independent Data Monitoring Committee will conduct an interim analysis of the ...

Foghorn Therapeutics Inc. FHTX recently announced that the FDA has placed a full clinical hold on the phase I dose escalation study of pipeline candidate FHD-286 in relapsed and/or refractory acute ...

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel ...

NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of ...